SurExam Life Science & Technology (Shenzhen) Co. has been granted the right to develop a test for early stage ovarian cancer in China that was discovered at Yale School of Medicine. Dr. Jiasen Xu, chief executive officer of SurExam, is a graduate of Yale. The new test uses proteins that the body produces in response to a tumor, along with the tumor proteins, which gives the test the ability to detect both early- and late-stage ovarian cancer with a 99% accuracy. More details...